New drug combo tested to control rare ovarian cancer
NCT ID NCT03531645
Summary
This study is testing if a combination of two drugs, fulvestrant and abemaciclib, can help control advanced low-grade serous ovarian cancer. The treatment is given before and after surgery. The goal is to see if this approach shrinks or stabilizes the cancer and is safe for the 18 women participating.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS OF FEMALE GENITAL ORGANS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.